Chemotherapy of metastatic carcinoma of the breast.
| dc.contributor.author | Hancock, B | |
| dc.contributor.author | Todd, Ian D | |
| dc.contributor.author | Wilkinson, Peter M | |
| dc.date.accessioned | 2011-06-14T17:39:47Z | |
| dc.date.available | 2011-06-14T17:39:47Z | |
| dc.date.issued | 1980-07 | |
| dc.identifier.citation | Chemotherapy of metastatic carcinoma of the breast. 1980, 31 (4):433-6 Clin Radiol | en |
| dc.identifier.issn | 0009-9260 | |
| dc.identifier.pmid | 7418343 | |
| dc.identifier.doi | 10.1016/S0009-9260(80)80184-X | |
| dc.identifier.uri | http://hdl.handle.net/10541/133130 | |
| dc.description.abstract | Thirty-four patients with metastatic breast carcinoma were treated with the following combination: methotrexate 60 mg/m2 i.v. days 1 and 8,5-fluorouracil 500 mg/m2 i.v. days 1 and 8, cyclophosphamide 100 mg/m2 daily for 14 days, and prednisolone 25 mg b.d. by mouth daily for 14 days. In 21/34 (62%) patients regression of tumour was maintained for at least three months and in six (18%) this was complete. The median duration of response was 15 months (range 6--33) and there was a significant difference in survival between responders and non-responders (P<0.01). Toxicity was acceptable although dose reduction was necessary in eight patients and in three patients treatment had to be discontinued. | |
| dc.language.iso | en | en |
| dc.subject | Breast Cancer | en |
| dc.subject.mesh | Adult | |
| dc.subject.mesh | Antineoplastic Agents | |
| dc.subject.mesh | Breast Neoplasms | |
| dc.subject.mesh | Cyclophosphamide | |
| dc.subject.mesh | Drug Therapy, Combination | |
| dc.subject.mesh | Female | |
| dc.subject.mesh | Fluorouracil | |
| dc.subject.mesh | Humans | |
| dc.subject.mesh | Methotrexate | |
| dc.subject.mesh | Middle Aged | |
| dc.subject.mesh | Prednisolone | |
| dc.subject.mesh | Prospective Studies | |
| dc.title | Chemotherapy of metastatic carcinoma of the breast. | en |
| dc.type | Article | en |
| dc.contributor.department | Departments of Radiotherapy and Clinical Pharmacology, Christie Hospital and Holt Radium Institute, Withington, Manchester, UK | en |
| dc.identifier.journal | Clinical Radiology | en |
| html.description.abstract | Thirty-four patients with metastatic breast carcinoma were treated with the following combination: methotrexate 60 mg/m2 i.v. days 1 and 8,5-fluorouracil 500 mg/m2 i.v. days 1 and 8, cyclophosphamide 100 mg/m2 daily for 14 days, and prednisolone 25 mg b.d. by mouth daily for 14 days. In 21/34 (62%) patients regression of tumour was maintained for at least three months and in six (18%) this was complete. The median duration of response was 15 months (range 6--33) and there was a significant difference in survival between responders and non-responders (P<0.01). Toxicity was acceptable although dose reduction was necessary in eight patients and in three patients treatment had to be discontinued. |